Drugs / Relmapirazin
Relmapirazin
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04008121 | Nov 2025 → Dec 2026 expected | diabetic retinopathy, macular degeneration, retinal vein occlusion | MediBeacon | Recruiting | No outcome recorded |
| Phase 0 | NCT03962998 | Oct 2019 → Oct 2021 | small bowel Crohn disease | MediBeacon | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT07080008 | Jan → Dec 2026 expected | ureteral disorder | MediBeacon | Recruiting | No outcome recorded |
| Phase 1 | NCT04318678 | Jul 2020 → Jul 2029 expected | CD4+/CD56+ hematodermic neoplasm, T-cell acute lymphoblastic leukemia, acute myeloid leukemia | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04109482 | Feb 2020 → May 2023 | CD4+/CD56+ hematodermic neoplasm | Mustang Bio | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02772276 | May 2016 → Aug 2021 | acute kidney injury | MediBeacon | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05777174 | Mar 2023 → Apr 2024 | kidney failure | MediBeacon | Completed | No outcome recorded |
| Phase 3 | NCT05425719 | Jun 2022 → Feb 2023 | chronic kidney disease | MediBeacon | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03473457 | Apr 2018 → Dec 2020 | acute myeloid leukemia | Zhujiang Hospital | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07643467 Background | Jul 2026 → May 2028 expected | — | Aaron Cook | Not yet recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Relmapirazin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07643467 ↗ |
| Known as | CD123-CART | “one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART therapy in Acute myeloid leukemia(AML)” NCT03473457 ↗ |
| Known as | Lumitrace | “IV push of relmapirazin (Lumitrace) prior to use of the tGFR device” NCT07643467 ↗ |
| Known as | MB-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04008121 ↗ |
| Known as | Relmapirazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1949708 ↗ |
| Known as | Relmapirazine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1949708 ↗ |
| Modality | Diagnostic / imaging agent | “fluorescent GFR tracer agent relmapirazin” PMID 39918882 ↗ Feb 2025 |
| Route | Intravenous | “4 µmol/kg administered by intravenous injection over 30 seconds” NCT02772276 ↗ |